Gender medicine in the US: how the Cass review failed to land
A landmark investigation with bearing on the future of gender ID services for minors has been pivotal in the UK—and largely ignored by US medical organisations and media, reports @WritingBlock for The BMJ.
🧵⬇️

In a recent interview, a German child and adolescent psychiatrist Dr. Korte discussed the German situation regarding youth transitions. He objects to the notion that a physician should be 'a kind of notary who accepts and confirms the patient's self-diagnosis.'

Dr. Korte

A thread by Will Malone MD about the Endocrine Society rationale for using puberty blockers for GD youth in 2017. New systematic reviews of evidence demand a reconsideration of the risk-benefit ratio, with the evidence of benefits lacking, while the concerns of harms are mounting.

We have updated our website with some additional facts about the German resolution to restrict all forms of youth gender transitions to controlled clinical trials (and after any pre-existing mental health problems have been adequately treated).

segm.org/German-resolut…

The European Society of Child and Adolescent Psychiatry (ESCAP)'s policy statement on child and adolescent gender dysphoria, which called for the 'first do no harm' approach, continues to reverberate in Europe. Last week it, was profiled in one of Netherland's national

The European Society of Child and Adolescent Psychiatry (ESCAP) published a policy statement on child and adolescent gender dysphoria, calling on healthcare providers to 'not to promote experimental and unnecessarily invasive treatments with unproven psycho-social effects and,